Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China

Cancer statistics in China, 2015

Wanqing Chen, Rongshou Zheng, Peter D. Baade et al. · CA A Cancer Journal for Clinicians · 2016 · 18K citations · Full text

Medicine, Oncology, Population Health Sciences +17

The National Comprehensive Cancer Network

William T. McGivney · Cancer · 1998 · 16.9K citations

Medicine, Oncology, Clinical Informatics +15

Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Yuichiro Ohe, Johan Vansteenkiste et al. · New England Journal of Medicine · 2017 · 5.3K citations · Full text

Medicine, Oncology, Pharmacology +16

Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?

Hans‐Georg Eichler, Sheldon X. Kong, William C. Gerth et al. · Value in Health · 2004 · 803 citations · Full text

Pharmacy, Economics, Pharmacoeconomics +15

Osimertinib As First-Line Treatment of <i>EGFR</i> Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Suresh S. Ramalingam, James Chih‐Hsin Yang, Chee Khoon Lee et al. · Journal of Clinical Oncology · 2017 · 536 citations

Medicine, Oncology, Pharmacology +14